Black Health
Calcium-channel blocker Hypertension Angina Coronary artery disease

Amlodipine (Norvasc, Katerzia) and Black patients

Brand names: Norvasc, Katerzia

Last reviewed: Sources checked:

What Amlodipine does

Amlodipine is a long-acting dihydropyridine calcium-channel blocker that relaxes the smooth muscle lining of arteries, widening them and lowering blood pressure. It's taken once a day by mouth, has a long half-life that forgives occasional missed doses, and is on virtually every pharmacy's $4 generic list.

What the evidence says for Black patients

Amlodipine is one of two guideline-preferred first-line antihypertensives for Black adults without CKD or heart failure (the other being a thiazide-type diuretic). This preference is grounded in strong outcome evidence:

  • The ALLHAT trial enrolled 15,094 Black participants — the largest hypertension outcome trial ever conducted in Black adults — and found that amlodipine produced equivalent all-cause mortality and coronary heart-disease outcomes to chlorthalidone and was superior to lisinopril for stroke and combined cardiovascular disease in the Black subgroup (Wright et al., JAMA 2005;293:1595–1608, PMID 15811979).
  • The BP-lowering effect of amlodipine in Black patients is at least as large as in white patients, in contrast to ACE inhibitors where the effect is measurably smaller.
  • Amlodipine is safe in CKD and does not require dose adjustment for kidney function, which matters given the disproportionate burden of CKD among Black adults.

The only guideline-based caveat is that amlodipine alone does not slow the progression of hypertensive kidney disease in Black adults — AASK showed an ACE inhibitor was superior for that specific outcome (Agodoa et al., JAMA 2001;285:2719–28). So when CKD is present, amlodipine is typically combined with (rather than replaced by) an ACE inhibitor or ARB.

Common alternatives

Other first-line options for Black adults with uncomplicated hypertension: chlorthalidone or indapamide (thiazide-type diuretics, ALLHAT-validated). When single-drug therapy is insufficient, amlodipine combines well with an ACE inhibitor or ARB — the ACCOMPLISH trial (Jamerson et al., NEJM 2008;359:2417–28, PMID 19052124) found benazepril-plus-amlodipine superior to benazepril-plus-HCTZ for cardiovascular outcomes, including in the Black subgroup.

Side effects

  • Peripheral edema — ankle and leg swelling, dose-related, occurs in roughly 10–30 percent at higher doses. More common in women. Often improves by pairing amlodipine with an ACE inhibitor or ARB.
  • Flushing, especially in the first few weeks
  • Headache, dizziness
  • Gingival hyperplasia with long-term use (rare)
  • Reflex tachycardia (uncommon with amlodipine compared to other dihydropyridines)

Factors that affect adherence

Peripheral edema is the leading reason patients discontinue amlodipine, and the edema can be misattributed to heart failure or kidney disease — leading to unnecessary work-up and sometimes diuretic escalation. Ask specifically about ankle swelling at every follow-up. Generic amlodipine is inexpensive and widely covered.

Questions to ask your doctor

Bring this list to your next appointment.

  • Is amlodipine alone enough for me, or do I need a second agent?
  • If I have kidney disease, should we add an ACE inhibitor or ARB?
  • What should I do if my ankles swell?
  • Can I take amlodipine with grapefruit juice? (Small amounts are fine; large daily intake can raise drug levels.)

References

  1. Wright JT Jr, Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005;293:1595–1608. PMID 15811979.
  2. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients (ACCOMPLISH). NEJM. 2008;359:2417–2428. PMID 19052124.
  3. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA Hypertension Guideline. Hypertension. 2018;71:e13–e115. DOI: 10.1161/HYP.0000000000000065.
  4. U.S. Food and Drug Administration. Norvasc (amlodipine besylate) label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019787s049lbl.pdf

Medical disclaimer

This page is patient education, not prescribing guidance. It summarizes the published evidence about how this medication has been studied in Black patients — it is not a substitute for the judgment of your personal clinician. Never start, stop, or change a prescription based on something you read here. If you have questions about your medication, call your prescriber or pharmacist. For emergencies, call 911.

Read our editorial standards for how we source, review, and update these pages.